Cargando…

Metabolic signatures differentiate ovarian from colon cancer cell lines

BACKGROUND: In this era of precision medicine, the deep and comprehensive characterization of tumor phenotypes will lead to therapeutic strategies beyond classical factors such as primary sites or anatomical staging. Recently, “-omics” approached have enlightened our knowledge of tumor biology. Such...

Descripción completa

Detalles Bibliográficos
Autores principales: Halama, Anna, Guerrouahen, Bella S, Pasquier, Jennifer, Diboun, Ilhem, Karoly, Edward D, Suhre, Karsten, Rafii, Arash
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4499939/
https://www.ncbi.nlm.nih.gov/pubmed/26169745
http://dx.doi.org/10.1186/s12967-015-0576-z
_version_ 1782380860793683968
author Halama, Anna
Guerrouahen, Bella S
Pasquier, Jennifer
Diboun, Ilhem
Karoly, Edward D
Suhre, Karsten
Rafii, Arash
author_facet Halama, Anna
Guerrouahen, Bella S
Pasquier, Jennifer
Diboun, Ilhem
Karoly, Edward D
Suhre, Karsten
Rafii, Arash
author_sort Halama, Anna
collection PubMed
description BACKGROUND: In this era of precision medicine, the deep and comprehensive characterization of tumor phenotypes will lead to therapeutic strategies beyond classical factors such as primary sites or anatomical staging. Recently, “-omics” approached have enlightened our knowledge of tumor biology. Such approaches have been extensively implemented in order to provide biomarkers for monitoring of the disease as well as to improve readouts of therapeutic impact. The application of metabolomics to the study of cancer is especially beneficial, since it reflects the biochemical consequences of many cancer type-specific pathophysiological processes. Here, we characterize metabolic profiles of colon and ovarian cancer cell lines to provide broader insight into differentiating metabolic processes for prospective drug development and clinical screening. METHODS: We applied non-targeted metabolomics-based mass spectroscopy combined with ultrahigh-performance liquid chromatography and gas chromatography for the metabolic phenotyping of four cancer cell lines: two from colon cancer (HCT15, HCT116) and two from ovarian cancer (OVCAR3, SKOV3). We used the MetaP server for statistical data analysis. RESULTS: A total of 225 metabolites were detected in all four cell lines; 67 of these molecules significantly discriminated colon cancer from ovarian cancer cells. Metabolic signatures revealed in our study suggest elevated tricarboxylic acid cycle and lipid metabolism in ovarian cancer cell lines, as well as increased β-oxidation and urea cycle metabolism in colon cancer cell lines. CONCLUSIONS: Our study provides a panel of distinct metabolic fingerprints between colon and ovarian cancer cell lines. These may serve as potential drug targets, and now can be evaluated further in primary cells, biofluids, and tissue samples for biomarker purposes. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s12967-015-0576-z) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-4499939
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-44999392015-07-14 Metabolic signatures differentiate ovarian from colon cancer cell lines Halama, Anna Guerrouahen, Bella S Pasquier, Jennifer Diboun, Ilhem Karoly, Edward D Suhre, Karsten Rafii, Arash J Transl Med Research BACKGROUND: In this era of precision medicine, the deep and comprehensive characterization of tumor phenotypes will lead to therapeutic strategies beyond classical factors such as primary sites or anatomical staging. Recently, “-omics” approached have enlightened our knowledge of tumor biology. Such approaches have been extensively implemented in order to provide biomarkers for monitoring of the disease as well as to improve readouts of therapeutic impact. The application of metabolomics to the study of cancer is especially beneficial, since it reflects the biochemical consequences of many cancer type-specific pathophysiological processes. Here, we characterize metabolic profiles of colon and ovarian cancer cell lines to provide broader insight into differentiating metabolic processes for prospective drug development and clinical screening. METHODS: We applied non-targeted metabolomics-based mass spectroscopy combined with ultrahigh-performance liquid chromatography and gas chromatography for the metabolic phenotyping of four cancer cell lines: two from colon cancer (HCT15, HCT116) and two from ovarian cancer (OVCAR3, SKOV3). We used the MetaP server for statistical data analysis. RESULTS: A total of 225 metabolites were detected in all four cell lines; 67 of these molecules significantly discriminated colon cancer from ovarian cancer cells. Metabolic signatures revealed in our study suggest elevated tricarboxylic acid cycle and lipid metabolism in ovarian cancer cell lines, as well as increased β-oxidation and urea cycle metabolism in colon cancer cell lines. CONCLUSIONS: Our study provides a panel of distinct metabolic fingerprints between colon and ovarian cancer cell lines. These may serve as potential drug targets, and now can be evaluated further in primary cells, biofluids, and tissue samples for biomarker purposes. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s12967-015-0576-z) contains supplementary material, which is available to authorized users. BioMed Central 2015-07-14 /pmc/articles/PMC4499939/ /pubmed/26169745 http://dx.doi.org/10.1186/s12967-015-0576-z Text en © Halama et al. 2015 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research
Halama, Anna
Guerrouahen, Bella S
Pasquier, Jennifer
Diboun, Ilhem
Karoly, Edward D
Suhre, Karsten
Rafii, Arash
Metabolic signatures differentiate ovarian from colon cancer cell lines
title Metabolic signatures differentiate ovarian from colon cancer cell lines
title_full Metabolic signatures differentiate ovarian from colon cancer cell lines
title_fullStr Metabolic signatures differentiate ovarian from colon cancer cell lines
title_full_unstemmed Metabolic signatures differentiate ovarian from colon cancer cell lines
title_short Metabolic signatures differentiate ovarian from colon cancer cell lines
title_sort metabolic signatures differentiate ovarian from colon cancer cell lines
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4499939/
https://www.ncbi.nlm.nih.gov/pubmed/26169745
http://dx.doi.org/10.1186/s12967-015-0576-z
work_keys_str_mv AT halamaanna metabolicsignaturesdifferentiateovarianfromcoloncancercelllines
AT guerrouahenbellas metabolicsignaturesdifferentiateovarianfromcoloncancercelllines
AT pasquierjennifer metabolicsignaturesdifferentiateovarianfromcoloncancercelllines
AT dibounilhem metabolicsignaturesdifferentiateovarianfromcoloncancercelllines
AT karolyedwardd metabolicsignaturesdifferentiateovarianfromcoloncancercelllines
AT suhrekarsten metabolicsignaturesdifferentiateovarianfromcoloncancercelllines
AT rafiiarash metabolicsignaturesdifferentiateovarianfromcoloncancercelllines